Improved CEDIA(R) benzodiazepine assay eliminates sertraline crossreactivity
Improved CEDIA(R) benzodiazepine assay eliminates sertraline crossreactivity
复制标题
DOI：
10.1093/jat/21.1.32
复制
发表时间：
1997-01-01
影响因子：
2.5
通讯作者：
Herold, DA
中科院分区：
文献类型：
--
作者：
Fitzgerald, RL;Herold, DA
最初的实验表明，原始CEDIA（克隆酶供体免疫测定法）苯二氮卓类检测试剂盒与舍曲林和舍曲林代谢物发生交叉反应。针对这一现象，Boehringer曼海姆Corporation开发了一种改进的CEDIA苯二氮卓类检测方法，以消除舍曲林交叉反应性。与原始CEDIA产品、EMIT II（酶倍增免疫测定技术）苯二氮卓类测定和电子捕获负化学电离（ECNCI）气相色谱-质谱法（GC-MS）对比，评价了改进的CEDIA测定。通过免疫测定法对531例尿液药物筛查进行了检测。对于5-芳基-7-氯-1，4-苯并二氮杂化合物，这些免疫测定的灵敏度和特异性对于改进的CEDIA测定分别为92%和98%;对于当前的CEDIA测定分别为92%和93%;对于EMIT II分别为87%和98%。改进的CEDIA测定法与EMIT II测定法几乎相同，两者都比原始CEDIA产品具有显著优势，原始CEDIA产品由于舍曲林代谢物而具有交叉反应性。采用ECNCI GC-MS首次在人尿液标本中鉴定出舍曲林的α3-羟基酮代谢产物。
Initial experiments demonstrated that the original CEDIA (cloned enzyme donor immunoassay) benzodiazepine assay crossreacted with sertraline and sertraline metabolites. In response to this phenomenon, Boehringer Mannheim Corporation developed an improved CEDIA benzodiazepine assay in order to eliminate sertraline crossreactivity. The improved CEDIA assay was evaluated against the original CEDIA product, EMIT II (enzyme multiplied immunoassay technique) benzodiazepine assay, and electron capture negative chemical ionization (ECNCI) gas chromatography-mass spectrometry (GC-MS). Five hundred and thirty-one urine drug screens were tested by the immunoassays. Sensitivity and specificity of these immunoassays for the 5-aryl-7-chloro-1,4-benzodiazepine compounds were 92 and 98%, respectively, for the improved CEDIA assay; 92 and 93%, respectively, for the current CEDIA assay; and 87 and 98%, respectively, for EMIT II. The improved CEDIA assay performed almost identically to the EMIT II assay, both of which had a significant advantage over the original CEDIA product, which was subject to crossreactivity because of sertraline metabolites. The α3-hydroxy ketone metabolites of sertraline are identified in human urine specimens for the first time using ECNCI GC-MS.